中国医药导刊
中國醫藥導刊
중국의약도간
Chinese Journal of Medical Guide
2015年
10期
1035-1038
,共4页
BACOD方案%静脉滴注%持续静脉输注%复发难治性弥漫大B细胞淋巴瘤%比较
BACOD方案%靜脈滴註%持續靜脈輸註%複髮難治性瀰漫大B細胞淋巴瘤%比較
BACOD방안%정맥적주%지속정맥수주%복발난치성미만대B세포림파류%비교
BACOD program%Intravenous infusion%Continuous intravenous infusion%Relapsed or refractory diffuse large B-cell lymphoma%Compare
目的:比较博来霉素+环磷酰胺+长春地辛+阿糖胞苷+地塞米松(BACOD)方案静脉滴注与持续静脉输注在复发难治性弥漫大B细胞淋巴瘤中的治疗效果。方法:运用随机整群抽样的方法选取我院2012年1月~2013年9月收治的126例复发难治性弥漫大B细胞淋巴瘤患者,依据随机数字表法将这些患者分为研究组和对照组两组,各63例。给予研究组患者改良BACOD方案治疗,给予对照组患者常规BACOD方案治疗,然后对两组患者的临床疗效、中位OS时间、3年和5年OS率及不良反应发生情况进行统计分析。结果:研究组患者治疗的总有效率(71.4%)显著高于对照组(63.5%)(P<0.05),中位OS时间显著长于对照组(P<0.05),3年和5年OS率(47.6%)、(38.1%)均显著高于对照组(12.7%)、(7.9%)(P<0.05),Ⅲ~Ⅳ度血小板减少(61.9%)显著高于对照组(17.5%)(P<0.05),但两组患者各程度粒细胞减少、消化道反应、发热、肝功能异常、肺间质改变发生率之间的差异无统计学意义(P>0.05)。结论:BACOD方案持续静脉输注在复发难治性弥漫大B细胞淋巴瘤中的治疗效果较静脉滴注显著。
目的:比較博來黴素+環燐酰胺+長春地辛+阿糖胞苷+地塞米鬆(BACOD)方案靜脈滴註與持續靜脈輸註在複髮難治性瀰漫大B細胞淋巴瘤中的治療效果。方法:運用隨機整群抽樣的方法選取我院2012年1月~2013年9月收治的126例複髮難治性瀰漫大B細胞淋巴瘤患者,依據隨機數字錶法將這些患者分為研究組和對照組兩組,各63例。給予研究組患者改良BACOD方案治療,給予對照組患者常規BACOD方案治療,然後對兩組患者的臨床療效、中位OS時間、3年和5年OS率及不良反應髮生情況進行統計分析。結果:研究組患者治療的總有效率(71.4%)顯著高于對照組(63.5%)(P<0.05),中位OS時間顯著長于對照組(P<0.05),3年和5年OS率(47.6%)、(38.1%)均顯著高于對照組(12.7%)、(7.9%)(P<0.05),Ⅲ~Ⅳ度血小闆減少(61.9%)顯著高于對照組(17.5%)(P<0.05),但兩組患者各程度粒細胞減少、消化道反應、髮熱、肝功能異常、肺間質改變髮生率之間的差異無統計學意義(P>0.05)。結論:BACOD方案持續靜脈輸註在複髮難治性瀰漫大B細胞淋巴瘤中的治療效果較靜脈滴註顯著。
목적:비교박래매소+배린선알+장춘지신+아당포감+지새미송(BACOD)방안정맥적주여지속정맥수주재복발난치성미만대B세포림파류중적치료효과。방법:운용수궤정군추양적방법선취아원2012년1월~2013년9월수치적126례복발난치성미만대B세포림파류환자,의거수궤수자표법장저사환자분위연구조화대조조량조,각63례。급여연구조환자개량BACOD방안치료,급여대조조환자상규BACOD방안치료,연후대량조환자적림상료효、중위OS시간、3년화5년OS솔급불량반응발생정황진행통계분석。결과:연구조환자치료적총유효솔(71.4%)현저고우대조조(63.5%)(P<0.05),중위OS시간현저장우대조조(P<0.05),3년화5년OS솔(47.6%)、(38.1%)균현저고우대조조(12.7%)、(7.9%)(P<0.05),Ⅲ~Ⅳ도혈소판감소(61.9%)현저고우대조조(17.5%)(P<0.05),단량조환자각정도립세포감소、소화도반응、발열、간공능이상、폐간질개변발생솔지간적차이무통계학의의(P>0.05)。결론:BACOD방안지속정맥수주재복발난치성미만대B세포림파류중적치료효과교정맥적주현저。
Objective: To compare the effects of Bleomycin + cyclophosphamide + vindesine cytarabine dexamethasone(BACOD) program intravenous infusion with continuous infusion in the treatment of relapsed or refractory diffuse large B-cell lymphoma. Methods:126 cases of relapsed or refractory diffuse large B-cell lymphoma patients who were treated in our hospital from January 2012 to September 2013 were selected by random cluster sampling,these patients were divided into study group and control group based on the random number table,63 cases each.Study patients were administered modified BACOD regimen,administered to the control group of patients routine BACOD regimen,and clinical efficacy,the median OS time,3-year and 5-year OS rate of adverse events of the two groups of patients were statistically analyzed.Results:The total efficiency of the study group (71.4%) was significantly higher than the control group (63.5%) (P<0.05),the median OS time was significantly longer(P<0.05),the 3 years and 5-year OS rate (47.6%),(38.1%) were significantly higher than the control group (12.7%),(7.9%) (P<0.05),theⅢ~Ⅳ thrombocytopenia (61.9%) was significantly higher than the control group (17.5%) (P<0.05), but the differences of the incidences of each degree of neutropenia,gastrointestinal reactions,fever, liver dysfunction,interstitial lung changes between the two groups were not statistically significant (P>0.05).Conclusion:The effects of BACOD continuous infusion program are more significant in the treatment of relapsed or refractory diffuse large B-cell lymphoma therapeutic than intravenous infusion.